Research & Development
Coronary Artery Disease
Epigenetics testing firm Cardio Diagnostics goes public on Nasdaq
At the core of its cardiovascular solutions is the Integrated Genetic-Epigenetic Engine, developed at the University of Iowa.
October 26, 2022
Boston Heart Diagnostics launches polygenic risk map
The risk map leverages polygenic risk scores (PRS) to provide physicians with an understanding of a patient's absolute genetic risk of complex disease, allowing for the creation of early, personalized intervention strategies, the firm said.
September 12, 2022
Polygenic score predicts risk of sudden cardiac death
In the study, published by researchers at Cedars-Sinai Medical Center in Los Angeles and collaborators elsewhere, patients with coronary artery disease but without severely impaired heart function received the highest polygenic risk score, indicating a 77% increased risk for sudden cardiac death.
August 28, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Study identifies risk factors for death from coronavirus
In the observational study, Dr. Bin Cao of Capital Medical University and colleagues from China examined the data of 191 patients with confirmed COVID-19 at two different hospitals. The median age of the patients was 56 and nearly 30% died in the hospitals. They also had various comorbidities, the most common being hypertension (30% of patients), diabetes (19%), and coronary artery disease (8%).
March 10, 2020
Genetic risk scoring not ready for prime time in heart disease
One study evaluated risk scoring in a cohort of participants in UK Biobank, a nonprofit research project that is performing whole genome sequencing on a mass scale in the U.K. The observational study assessed polygenic risk scores, pooled cohort equations (risk prediction models), and both combined for predicting events in 352,660 participants with no cardiovascular disease at baseline.
February 18, 2020
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Should blood donations be screened for high cholesterol?
Familial hypercholesterolemia is found in 1 in 250 individuals in the general population, and it can lead to premature coronary artery disease (CAD) due to elevated levels of low-density lipoprotein (LDL) cholesterol. The condition is underdiagnosed and undertreated, although it is easily detected through blood lipid profiles or genetic testing; treatment includes statins, which effectively reduce LDL cholesterol levels.
May 22, 2019
Gencove scores NIH small business grant
The amount of the grant was not disclosed.
April 25, 2019
Page 1 of 1